Current Clinical Trials

Phase 1

No	Site	Stage of cancer	Title of study	Principal investigator	Details of trial	Status
1	Pancreas	Adv 2nd/3rd line	NCC-13-01 Phase I trial of OXIRI [oxaliplatin (O), xeloda (X) and irinotecan (I)] treatment in patients with advanced and/or metastatic pancreatic adenocarcinoma	Dr Matthew Ng	NCT02368860	Open
2	All Solid Tumour	IV	D3-002 A Phase 1A/B study to evaluate the safety and tolerability of ET-1922159 in advanced solid tumours	Dr Matthew Ng	NCT02521844	On hold
3	All Solid Tumour	FGFR expressions and fusion	Debio 1347-101 A phase I, gene alteration-based, open label, multicenter study of oral Debio 1347 (CH5183284) in patients with advanced solid malignancies, whose tumours have an alteration of the FGFR 1, 2 or 3 genes	Dr Matthew Ng	NCT01948297	Open
4	Breast	IV	CLSZ102X2101 A phase I/Ib, open label study of LSZ102 single agent and LSZ102 in combination with either LEE011 (LSZ102 + LEE011) or BYL719 (LSZ102 + BYL719) in patients with advanced or metastatic ER+ breast cancer who have progressed after endocrine therapy	Dr Yap Yoon Sim	NCT02734615	Open
5	All Solid Tumour	IV	CPDR001X2103 Phase Ib, open-label, multi-center study to characterize the safety, tolerability and pharmacodynamics (PD) of PDR001 in combination with CJM112, EGF816, Ilaris® (canakinumab) or Mekinist® (trametinib)	Dr David Tai	NCT02900664	Open
6	All Solid Tumour	IV	CMAK683X2101 A Phase I/II, multicenter, open-label study of MAK683 in adult patients with advanced malignancies	Dr Daniel Tan	NCT02900651	Open
7	All Solid Tumour	IV	CBLZ945X2101 A Phase I/II, open-label, multi-center of the safety and efficacy of BZL945 as single agent and in combination with PDR001 in adults patients with advanced solid tumors malignancies.	Dr Darren Lim	NCT02829723	Open
8	Ovarian, tubal or peritoneal origin epithelial cancer	Recurrent	ORION-01 / NCCOV-02 Prospective Phase Ib-II clinical trial to evaluate the safety and activity of Oregovomab and Nivolumab as a combinatorial immunotherapy strategy in patients with recurrent epithelial cancer of ovarian, tubal or Peritoneal Origin	Dr Jack Chan	NCT03100006	On hold
9	All Solid Tumour	IV	CTNO155X2101 An Open-label, multi-center, Phase I, dose finding study of oral TNO155 in adult patients with advanced solid tumors	Dr Daniel Tan	NCT03114319	Open
10	CRC and PDAC	Advanced	CTMT212XSG01T Phase Ib study evaluating safety and tolerability of combination trametinib and ruxolitinib in patients with advanced RAS mutant colorectal cancer and pancreatic adenocarcinoma	Dr David Tai	Pending	Open
11	Lung	LOCALLY ADVANCED/ METASTATIC - First Line	CPDR001C2101 Phase 1b, multicenter, open label, 3 arm, dose de-escalation study of PDR001 in combination with platinum-doublet chemotherapy in 1st line, PD-L1 unselected, NSCLC patients	Dr Daniel Tan	NCT03064854	Open
12	All Solid Tumour	IV	15834 Phase 1b multi-indication study of anetumab ravtansine (BAY 94-9343) in patients with mesothelin expressing advanced or recurrent malignancies	Dr Matthew Ng	NCT03102320	Open
13	All Solid Tumour	documented RET infusion	LOXO-RET-17001 A Phase 1 Study of Oral LOXO-292 in Patients with Advanced Solid Tumors, Including RET-Fusion Non-Small Cell Lung Cancer, Medullary Thyroid Cancer, and Other Tumors with Increased RET Activity	Dr Daniel Tan	NCT03157128	Open
14	Non-small cell lung cancer	IV	CEGF816X2102 A phase Ib, open label, multi-center study to characterize the safety, tolerability and preliminary efficacy of EGF816 in combination with selected targeted agents in EGFR mutant NSCLC	Dr Daniel Tan	NCT03333343	Open
15	All Solid Tumour	documented RET infusion	BLU-667-1101 A Phase 1 Study of the Highly-selective RET inhibitor, BLU-667, in Patients with Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumours	Dr Daniel Tan	NCT03037385	Open
16	Non-small cell lung cancer	IV	MCLA-128-CL01 A Phase I/II Study of MCLA-128, a full length IgG1 Bispecific Antibody Targeting HER2 and HER3, in Patients with Solid Tumors	Dr Justina Lam	NCT02912949	Open
17	All Solid Tumour with documented NTRK fusions	must had prior TRK inhibitor	LOXO-EXT-17005 A Phase 1/2 study of the TRK Inhibitor LOXO-195 in Adult and Pediatric Subjects with Previously Treated NTRK fusion cancers	Dr Daniel Tan	NCT03215511	Open
18	All Solid Tumour	IV	CNZV930X2101 A Phase I/Ib, open-label, multi-center study of NZV930 as a single agent and in combination with PDR001 and/or NIR178 in patients with advanced malignancies	Dr David Tai	NCT03549000	Open
19	All Solid Tumour	IV	BAY 1163877 / 19774 A multicenter Phase 1 study to evaluate the safety, tolerability, pharmacokinetics, and maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of the combination of rogaratinib and copanlisib in patients with FGFR-positive, locally advanced or metastatic solid tumors	Dr Justina Lam	NCT03517956	Open
20	Pancreatic	not more than 2 prior lines	B9991033 A Phase 1b/2 study to evaluate safety and clinical activity of avelumab in combination with Binimetinib with or without talazoparib in patients with locally advanced or metastatic RAS-mutant solid tumors	Dr Daniel Tan	NCT03637491	On hold
21	All Solid Tumour	with documented ATM loss	BAY 1895344 / 18594 An open-label, first-in-human, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and maximum tolerated dose and / or recommended Phase II dose of the ATR inhibitor BAY 1895344 in patients with advanced solid tumors and lymphomas	Dr Daniel Tan	NCT03188965	Open
22	Breast	TNBC, not more than 2 prior lines of chemotherapy. Neoadjuvant or adjuvant chemotherapy will count as one prior line.	CADPT01A12101C A Phase Ib, multicenter, open-label dose escalation and expansion platform study of select immunotherapy combinations in adult patients with triple negative breast cancer	Dr Jack Chan	NCT03742349	Open
23	NSCLC	Advanced recurrent	BI 1200.275 A dose finding study of continuous and intermittent high-dose (HDI) Afatinib (EGFR Tyrosine Kinase Inhibitor) on CNS metastases and leptomeningeal disease (LMD) in patients with advanced refractory EGFR mutation positive non-small cell lung cancer	Dr Daniel Tan	NCT03711422	Open
24	All Solid Tumour	FGFR fusions	Debio 1347-201 A Phase II basket study of the oral selective pan-FGFR inhibitor Debio 1347 in subjects with solid tumors harboring a fusion of FGFR1, FGFR2 or FGFR3	Dr Matthew Ng	NCT03834220	Open
25	Liver	IV	D4191C00022 A Safety and Tolerability, and Clinical Activity of MEDI4736 and Tremelimumab Administered as Monotherapy and in Combination to Subjects with Unresectable Hepatocellular Carcinoma	Dr David Tai	NA	Open

Current clinical trials by body parts

No	Site	Stage of cancer	Title of study	Principal investigator	Details of trial	Status
1	Biliary	NA	STOCS Selective Internal Radiation Therapy with Yttrium-90 Resin Microspheres followed by Gemcitabine + Cisplatin for Intra-hepatic Cholangiocarcinoma	Dr David Tai	NA	Open
2	Bladder	Unresectable or Metastatic Urothelial Cancer	CA209-901 A Phase 3, Open-label, Randomized Study of Nivolumab Combined with Ipilimumab, or with Standard of Care Chemotherapy, versus Standard of Care Chemotherapy in Participants with Previously Untreated Unresectable or Metastatic Urothelial Cancer	Dr Ravindran Kanesvaran	NCT03036098	Open
3	Bladder	FGFR-positive locally advanced or metastatic urothelial carcinoma	17403 A randomized, open label, multicenter Phase 2/3 study to evaluate the efficacy and safety of rogaratinib (BAY 1163877) compared to chemotherapy in patients with FGFR-positive locally advanced or metastatic urothelial carcinoma who have received prior platinum-containing chemotherapy.	Dr Toh Chee Keong	NCT03410693	On hold
4	Breast	STAGE 4, BRAIN METS, 2nd LINE, HER2 +	ASLAN001-006 A phase II single arm trial to assess the efficacy of ASLAN001 plus capecitabine in previously irradiated, progressing central nervous system (CNS) metastases for HER2 positive breast cancer patients.	Dr Lee Guek Eng	NA	Open
5	Breast	HER2-, Hormone Receptor +, Advanced Breast Ca	CBYL719X2402 (BYLIEVE) A phase II, multicenter, open-label, two-cohort, non-comparative study to assess the efficacy and safety of alpelisib plus fulvestrant or letrozole in patients with PIK3CA mutant, hormone receptor (HR) positive, HER2-negative advanced breast cancer (aBC), who have progressed on or after CDK 4/6 inhibitor treatment	Dr Yap Yoon Sim	NCT03056755	Open
6	Breast	LA or MBC TNBC and HR(+) HER2 (-), 1st Line for LA/MBC	CO40016 A Double-Blind, Placebo-Controlled, Randomized Phase III Study of Ipatasertib in Combination with Paclitaxel as a Treatment for Patients with PIK3CA/ AKT1/ PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer	Dr Rebecca Dent	NCT03337724	Open
7	Breast	Inoperable LA/MBC, TNBC	MO39193 Phase III, Randomized, Double-Blind, Placebo-Controlled Multicenter Study of the Efficacy and Safety of Atezolizumab in Combination with Chemotherapy in Patients with Early Relapsing Recurrent (Inoperable Locally Advanced or Metastatic) Triple-Negative Breast Cancer	Dr Rebecca Dent	NCT03371017	Open
8	Breast	HER2+, Hormone Receptor+, LABC MBC	SYD985.002 (TULIP) A multi-centre, open-label, randomized clinical trial comparing the efficacy and safety of the antibody-drug conjugate SYD985 to physician's choice in patients with HER2- positive unresectable locally advanced or metastatic breast cancer	Dr Jack Chan	NCT03262935	Open
9	Breast	HR (ER and/or PgR) positive , MBC	ODO-TE-B301 A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane.	Dr Elaine Lim	NCT03326674	Open
10	Breast	TNBC LABC MBC 1st or 2nd line	CLAG525B2101 A phase II open-label, randomized, three-arm, multicenter study of LAG525 given in combination with spartalizumab (PDR001), or with spartalizumab and carboplatin, or with carboplatin, as first or second line therapy in patients with advanced triple-negative breast cancer	Dr Rebecca Dent	NCT03499899	Open
11	Breast	Inoperable LA/MBC, TNBC	DORA Phase II Multicenter Study of Olaparib or Olaparib and MEDI 4736 in Platinum Treated Triple Negative Breast Cancer	Dr Rebecca Dent	NCT03167619	Open
12	Breast	premenopausal perimenopausal HER2- HR+ LABC MBC	CLEE011A3201C A phase II randomized study of the combination of Ribociclib plus goserelin acetate with Hormonal Therapy versus physician choice chemotherapy in premenopausal or perimenopausal patients with hormone receptor-positive/HER2-negative inoperable locally advanced or metastatic breast cancer - RIGHT Choice Study	Dr Yap Yoon Sim	NCT03839823	Open
13	CRC	Neoadjuvant	OTSP-WoOCRC / MK-3475-886 Window of Opportunity Study with Neoadjuvant Pembrolizumab in MSS & MSI Colorectal Cancer	Dr Iain Tan	NCT03984578	Open
14	CRC	Adjuvant	ASCOLT Aspirin For Dukes C And High Risk Dukes B Colon Cancer – An International Multi-Centre, Double Blind, Randomized Placebo Controlled Phase III Trial	Dr Tham Chee Kian	NCT00565708	Open
15	Gastric/ Gastroesophageal Junction	ADJUVANT/ NEOADJUVANT	MK3475-585 A Phase III, Randomized, Double-Blind, Clinical Trial of Pembrolizumab (MK-3475) plus Chemotherapy (XP or FP) versus Placebo plus Chemotherapy (XP or FP) as Neoadjuvant/Adjuvant Treatment for Subjects with Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma (KEYNOTE-585)	Dr Matthew Ng	NCT03221426	Open
16	Gastric/ Gastroesophageal Junction	Adjuvant	CA209-577 A Randomized, Multicenter, Double Blind, Phase III Study of Adjuvant Nivolumab or Placebo in Subjects with Resected Esophageal, or Gastroesophageal Junction Cancer	Dr Matthew Ng	NCT02743494	Open
17	Gastric	Advance	BGB-290-303 A Phase 3, Double-blind, Randomized Study of BGB-290 versus Placebo as Maintenance Therapy in Patients with Inoperable Locally Advanced or Metastatic Gastric Cancer that Responded to Platinum-based First-line Chemotherapy	Dr Matthew Ng	NCT03427814	Open
18	Gastric/ Gastroesophageal Junction	Advance 1st line	CA224-060 A Randomized, Open-label, Phase II Clinical Trial of Relatlimab (anti-LAG-3) plus Nivolumab in Combination with Chemotherapy Versus Nivolumab in Combination with Chemotherapy as First-Line Treatment in Patients with Gastric or Gastroesophageal Junction Adenocarcinoma	Dr Matthew Ng	NCT03662659	Open
19	Gastric	Neoadjuvant	INNOVATION INtegratioN of trastuzumab, with or without pertuzumab, into periOperatiVe chemotherApy of HER-2 posiTIve stOmach caNcer (EORTC-1203-GITCG)	Dr Matthew Ng	NCT02205047	Open
20	GIST	Locally Advanced Unresectable/ Metastatic	BLU-285-1303 An International Multi-Centre Open-Label, Randomized, Phase 3 Study of BLU 285 vs Regorafenib in Patients with Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST).	Dr Nagavalli	NCT03465722	Open
21	GIST	Locally Advanced / Metastatic	DCC-2618-03-002 A Phase 3, Interventional, Randomized, Multicenter, Open-Label Study of DCC-2618 vs Sunitinib in Patients with Advanced Gastrointestinal Stromal Tumors after Treatment with Imatinib	Dr Nagavalli	NCT03673501	Open
22	Ovarian	Recurrent, Advanced	GY02/06/16 A Multicentre Phase II randomised trial of Durvulamab (MEDI4736) versus physician's choice chemotherapy in recurrent ovarian clear cell adenocarcinomas (MOCCA)	Dr Chay Wen Yee	NCT03405454	Open
23	Nasopharyngeal	LOCALLY RECURRENT / METASTATIC - 2nd LINE	CA209-796: A phase II trial of Ipililumab in combination with nivolumab in patients with advanced nasopharyngeal carcinoma	Dr Darren Lim	NCT03097939	On hold
24	Nasopharyngeal	T3-T4 disease without distant metastasis	MISSION16: 18F-FMISO PET guided dose escalation in nasopharyngeal carcinoma – a feasibility and planning study	Dr Kiattisa Sommat	NA	Open
25	Nasopharyngeal	Neoadjuvant / Stage IVA	NEO-SPACE Neoadjuvant Pembrolizumab-Gemcitabine-Cisplatin followed by Concurrent Pembrolizumab-Chemoradiation and Maintenance Pembrolizumab for Stage IVA Nasopharyngeal Cancer	Dr Darren Lim	NCT03734809	Open
26	NPC	LOCALLY ADVANCED/ METASTATIC - First Line	JS001-015-III-NPC Phase III, Randomized, Placebo-Controlled, Multicenter, Double-Blind Study Comparing JS001 Combined with Chemotherapy versus Placebo Combined with Chemotherapy for Recurrent or Metastatic Nasopharyngeal Cancer	Dr Darren Lim	NCT03581786	Open
27	Liver	LOCALLY ADVANCED / METASTATIC - ANY LINE	CA209-678 A Phase II Open-label, Single Centre, Non-randomized Trial of Y90-Radioembolization in combination with Nivolumab in Asian Patients with Advanced Hepatocellular Carcinoma.	Dr David Tai	NCT03033446	On hold
28	Liver	Adjuvant	CA2099DX A Phase 3, Randomized, Double-blind Study of Adjuvant Nivolumab versus Placebo for Participants with Hepatocellular Carcinoma Who Are at High Risk of Recurrence after Curative Hepatic Resection or Ablation	Dr David Tai	NCT03383458	Open
29	Lung	LOCALLY ADVANCED / METASTATIC - 2ND LINE/ 3RD LINE	CINC280A2201 A phase II, multicenter, three-cohort of oral cMET inhibitor INC280 in adult patients with EGFR wild-type (wt), advanced non-small cell lung cancer (NSCLC) who have received one or two prior lines of systemic therapy for advanced/ metastatic disease	Dr Ang Mei Kim	NCT02414139	Open
30	Lung	ADVANCED/ METASTATIC -2nd LINE and above	CA209-777 Randomised phase 2 study of nivolumab versus nivolumab and ipilimumab combination in EGFR mutant Non-small Cell Lung Cancer	Dr Tan Eng Huat	NCT03091491	Open
31	Lung	LOCALLY ADVANCED/ METASTATIC - First Line	BO29554 A Phase II/III Multicenter Study Evaluating the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Patients with Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Harboring Actionable Somatic Mutations Detected in Blood (B-FAST: Blood-First Assay Screening Trial)	Dr Daniel Tan	NCT03178552	Open
32	Lung	LOCALLY ADVANCED/ METASTATIC - First Line	MK-3475-495 A Phase 2 Precision Oncology Study of Biomarker-Directed, Pembrolizumab-(MK-3475, SCH 900475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (KEYNOTE-495; KeyImPaCT)	Dr Daniel Tan	NCT03516981	Open
33	Lung	ADJUVANT THERAPY	BO40336 A Phase III, Open-label, Randomized Study to Evaluate the Efficacy And Safety of Adjuvant Alectinib Versus Adjuvant Platinum-based Chemotherapy in Patients with Completely Resected Stage IB (Tumors ≥ 4 cm) to Stage IIIA Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer (ALINA)	Dr Toh Chee Keong	NCT03456076	Open
34	Lung	LOCALLY ADVANCED/ METASTATIC - 2nd Line	CACZ885V2301 A randomized, double-blind, placebo-controlled, phase III study evaluating the efficacy and safety of canakinumab in combination with docetaxel versus placebo in combination with docetaxel in subjects with non-small cell lung cancer (NSCLC) previously treated with PD-(L)1 inhibitors and platinum-based chemotherapy (CANOPY-2)	Dr Darren Lim	NCT03626545	Open
35	Lung	LOCALLY ADVANCED/ METASTATIC - First Line	CANOPY-1 A randomized, double-blind, placebo-controlled, phase III study evaluating the efficacy and safety of pembrolizumab plus platinum-based doublet chemotherapy with or without canakinumab as first line therapy for locally advanced or metastatic non-squamous and squamous non-small cell lung cancer subjects	Dr Tan Wan Ling	NCT03631199	Open
36	Lymphoma	RELAPSED	Bayer 17833 A Phase III, randomized, double-blind, controlled, multicenter study of intravenous PI3K inhibitor copanlisib in combination with standard mmunochemotherapy versus standard immunochemotherapy in patients with relapsed indolent non-Hodgkin’s lymphoma (iNHL) - CHRONOS-4	Dr Lim Soon Thye	NCT02626455	Open
37	Esophageal	LOCALLY ADVANCED / METASTATIC - 1ST LINE	CA209-648 A Randomized Phase 3 Study of Nivolumab plus Ipilimumab or Nivolumab Combined with Flurouracil plus Cisplatin versus Platinum Doublet Chemotherapy in Subjects with Inoperable Locally Advanced, Recurrent or Metastatic Previously Untreated Esophageal Squamous Cell Carcinoma	Dr Matthew Ng	NCT03143153	Open
38	Renal	Resectable Renal Cancer	CA209-914 A Phase 3 Randomized Study Comparing Nivolumab and Ipilimumab Combination vs Placebo in Participants with Localized Renal Cell Carcinoma Who Underwent Radical or Partial Nephrectomy and Who Are at High Risk of Relapse	Dr Ravindran Kanesvaran	NCT03138512	Open

General

No	Site	Stage of cancer	Title of study	Principal investigator	Details of trial	Status
1	SOLID TUMORS	LOCALLY ADVANCED / METASTATIC - ANY LINE	CLDK378A2X01B An open-label, multi-center, Phase IV, roll-over study in patients with ALK positive malignancies who have completed a prior Novartis-sponsored certinib (LDK378) study and are judged by the investigator to benefit from continued treatment with ceritinib	Dr Daniel Tan	NCT02584933	Open
2	SOLID TUMORS	LOCALLY ADVANCED / METASTATIC - ANY LINE	LOXO-TRK-15002 (NAVIGATE) A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Subjects with NTRK Fusion-Positive Tumors	Dr Daniel Tan	NCT02576431	Open
3	SOLID TUMORS	LOCALLY ADVANCED / METASTATIC - ANY LINE	RXDX-101-02 (STARTRK-2) An Open-label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements	Dr Daniel Tan	NCT02568267	Open
4	SOLID TUMORS	LOCALLY ADVANCED/ METASTATIC – 2nd Line Onwards	BP40234 An Open-label, Multicenter, Phase II Study to Evaluate the Therapeutic Activity of RO6874281, An Immunocytokine, Consisting of Interleukin-2 Variant (IL-2V) Targeting Fibroblast Activation Protein-A (FAP), in Combination with Atezolizumab (Anti-PD-L1), Administered Intravenously, in Participants with Advanced and/or Metastatic Solid Tumors	Dr Darren Lim	NCT03386721	On hold
5	SOLID TUMORS	LOCALLY ADVANCED/ METASTATIC – 2nd Line Onwards	CA209-848 A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H) (CheckMate 848: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 848)	Dr Iain Tan	NCT03668119	Open
6	SOLID TUMORS	LOCALLY ADVANCED/ METASTATIC – 2nd Line Onwards	CNIR178X2201 A Phase 2, multi-center, open label study of NIR178 in combination with PDR001 in patients with selected advanced solid tumors and non-Hodgkin lymphoma	Dr Daniel Tan	NCT03207867	Open